Biosimilar Antibodies are antibodies sharing identical active biological components with the original therapeutic antibodies, serving as positive controls for drug efficacy evaluation in scientific research and supporting functional validation of target proteins.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Rosnilimab is a Humanized Monoclonal antibody, expressed in Mammalian cells.
Sirukumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL6, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
Tildrakizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL23A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis 3. The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter 7. A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects 5.
Conatumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFRSF10B/CD262, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
Tibulizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL17A/TNFSF13B/CD257, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tibulizumab is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
Denosumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFSF11/CD254, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.
Modakafusp Alfa is a fusion monoclonal antibody biosimilar expressed in CHO cells, targeting ADPRC, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Teneliximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD40/TNFRSF5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Nadunolimab is a Humanized Monoclonal antibody, expressed in Mammalian cells.
Trastuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ERBB2 (HER2 , Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD/antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2, NGL), for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Suppliers
Request a product
Please provide the required information below so that we can quickly source your products.
